Adenovirus serotype 36

Adenovirus serotype 36 (Ad-36 or Adv36) is one of the many serotypes of the Adenoviridae family, which are medium-sized, nonenveloped viruses with an icosahedral nucleocapsid containing a double stranded DNA genome. Ad-36 is particularly notable for its association with obesity in humans and animals, a discovery that has led to significant research interest in its potential implications for understanding and managing obesity.

Discovery and Classification

Ad-36 was first isolated and identified in the late 1970s from the feces of a diabetic patient. It belongs to the Adenoviridae family, which is divided into several genera, with Ad-36 being part of the Mastadenovirus genus that infects mammals. The classification of adenoviruses is based on their ability to agglutinate red blood cells (hemagglutination) and their oncogenic (cancer-causing) potential in rodents, as well as on their genetic characteristics.

Structure and Genome

Like all adenoviruses, Ad-36 has a nonenveloped capsid that is icosahedral in shape. The virus particle encloses a linear double-stranded DNA genome. The genome of Ad-36 encodes several proteins that are involved in the virus replication cycle, including those that modulate the host's immune response, ensuring the virus's survival and propagation within the host.

Pathogenesis and Immune Response

Ad-36 infects a wide range of tissue types, including adipose (fat) tissue, which is believed to be central to its role in obesity. The virus enters host cells through receptor-mediated endocytosis, facilitated by the fiber knob protein of the virus binding to specific receptors on the host cell surface. Once inside, the virus hijacks the host cell's machinery to replicate and produce new virus particles. The immune response to Ad-36 infection involves both the innate and adaptive arms of the immune system, but the virus has evolved mechanisms to evade these responses, allowing for persistent infection in some cases.

Association with Obesity

Research has shown that Ad-36 is associated with an increased risk of obesity in humans and several animal models. Studies have found that infection with Ad-36 can lead to an increase in adiposity and significant weight gain, possibly through effects on adipocyte differentiation, lipid metabolism, and insulin sensitivity. However, the mechanisms by which Ad-36 influences obesity are not fully understood, and research is ongoing to elucidate these pathways and to determine the potential for therapeutic interventions.

Epidemiology

The prevalence of Ad-36 infection in human populations varies geographically, but seropositivity has been associated with obesity in both children and adults in multiple studies. The virus is transmitted through respiratory and fecal-oral routes, making it highly contagious. Despite its association with obesity, not all individuals infected with Ad-36 will become obese, suggesting that genetic, environmental, and lifestyle factors also play significant roles in the development of obesity.

Potential Therapeutic Implications

The discovery of Ad-36's association with obesity has sparked interest in the potential for antiviral therapies or vaccines to prevent or treat obesity. However, much more research is needed to understand the complex interactions between Ad-36 infection, host factors, and obesity, and to develop safe and effective interventions.

Conclusion

Adenovirus serotype 36 represents a fascinating intersection between virology and metabolic disease, highlighting the complex interplay between pathogens and host metabolism. As research continues, the insights gained from studying Ad-36 may contribute to novel approaches for understanding and managing obesity, a major public health challenge worldwide.